Document is current
Any future updates will be listed below
-
Authors
Ferreira, Natalia S.
Ferreira, Thalita C. S.
Sauter, Ismael P.
Brandt-Almeida, Deborah
Staquicini, Daniela I.
de Assis, Josiane B.
de Oliveira, Vivian C.
Júnior, José Wandilson Barboza Duarte
Claser, Carla
Popi, Ana Flavia
Pasqualini, Renata
Arap, Wadih
Cortez, Mauro
-
Funding
Funding for this research was provided by:
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (001, 001, 001)
Fundação de Amparo à Pesquisa do Estado de São Paulo (2013/14087-0, 2012/24105-3)
Levy-Longenbaugh Donor-Advised Fund
Conselho Nacional de Desenvolvimento Científico e Tecnológico (443816/2014-0)
- License Information
-
More Information
Article History
Received: 23 January 2025
Accepted: 19 August 2025
First Online: 29 September 2025
Declarations
:
: R.P. and W.A. are founders and equity shareholders of PhageNova Bio. R.P. is the Chief Scientific Officer of and serves as a paid consultant for PhageNova Bio. R.P. and W.A. are founders and equity shareholders of and serve as paid consultants for MBrace Therapeutics. R.P. and W.A. have Sponsored Research Agreements (SRAs) in place with PhageNova Bio and with MBrace Therapeutics. These arrangements are managed in accordance with the established institutional conflict-of-interest policies of Rutgers, The State University of New Jersey. This particular study falls outside of the scope of these SRAs. The subject matter of this publication falls outside of SRAs of PhageNova Bio and MBrace Therapeutics. All the remaining authors declare no conflict of interest.
